Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS). [More]
New tool may help identify high risk atherosclerotic plaques

New tool may help identify high risk atherosclerotic plaques

Researchers have developed and validated a new tool to help identify unstable or high risk atherosclerotic plaques--inflamed fatty deposits in the artery wall and a main contributor to cardiovascular disease (CVD). This breakthrough may lead to better identifying which plaques are considered at the highest risk for rupturing and causing a heart attack or stroke. [More]
Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies. [More]
FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg. [More]
Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual. [More]
Three researchers recognised for their contributions to Australian medical research

Three researchers recognised for their contributions to Australian medical research

Three top Walter and Eliza Hall Institute researchers have been recognised for their contributions to Australian medical research, with their election as fellows of the Australian Academy of Health and Medical Sciences. [More]
BMBF provides EUR 25 million to support CTH's Integrated Research and Treatment Centers program

BMBF provides EUR 25 million to support CTH's Integrated Research and Treatment Centers program

An international committee of experts has reviewed and recommended the funding of the Center for Thrombosis and Hemostasis at the Mainz University Medical Center for an additional five years. In accordance with this recommendation, the German Federal Ministry of Education and Research will be providing support of approximately EUR 25 million to the CTH within its Integrated Research and Treatment Centers (IFB) program. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
ElastiMed raises $1 million investment

ElastiMed raises $1 million investment

ElastiMed, a portfolio company of Trendlines Medical, announced this week that it raised $1 million, which includes an investment from Pix Vine Capital, a Singapore-based investment house. [More]
Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Acute Cardiovascular Care 2015 will highlight innovations and controversies in the field, guaranteeing great stories on topics relevant to the press. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
Novel radiopharmaceutical probe has potential to save lives of patients with ischemic stroke

Novel radiopharmaceutical probe has potential to save lives of patients with ischemic stroke

A novel radiopharmaceutical probe developed at Massachusetts General Hospital has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism - conditions caused when important blood vessels are blocked by a clot that has traveled from another part of the body. [More]
Experts present first comprehensive guide to using IV devices

Experts present first comprehensive guide to using IV devices

More than a billion times a year, doctors and nurses insert tiny tubes into the veins of American hospital patients, so they can deliver lifesaving medicines, give fluids and nutrition, monitor key vital signs, and help patients with conditions ranging from cancer and pain to kidney failure and serious infections. [More]
Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress. [More]
GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
PRESTIGE study suggests novel target to prevent stent thrombosis

PRESTIGE study suggests novel target to prevent stent thrombosis

Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated thrombotic processes may be a realistic target for novel therapies to prevent stent thrombosis. [More]

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial. [More]
DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year. [More]
STEMI study: Absorbable stents perform similarly to metallic stents

STEMI study: Absorbable stents perform similarly to metallic stents

A drug-eluting coronary stent made of absorbable material performed similarly to the gold-standard metal one in a non-inferiority trial among patients with the more serious type of heart attack known as ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial. [More]
Advertisement
Advertisement